Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25464230 | 0.88 | LMNA (0.32) | LMNAMAPTPOLB | |
| SCHEMBL10210462 | 0.74 | PIK3CD (0.37) | LMNAMAPTPOLB | |
| SCHEMBL25465102 | 0.69 | PIK3CD (0.34) | MAPTCYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL28357684 | 0.68 | CA1 (0.40) | LMNAMAPTPOLB | |
| SCHEMBL25465100 | 0.68 | DPP4 (0.32) | — | |
| SCHEMBL10210455 | 0.67 | PIK3CD (0.42) | LMNAMAPTPOLB | |
| SCHEMBL11930010 | 0.67 | SMN1; SMN2 (0.37) | MAPT | |
| SCHEMBL16472467 | 0.67 | PIK3CD (0.42) | LMNAMAPTPOLB | |
| SCHEMBL19449159 | 0.67 | PIK3CD (0.42) | LMNAMAPTPOLB | |
| SCHEMBL13394541 | 0.67 | OPRM1 (0.32) | LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | LMNA 4729/4885MAPT 3199/4885CYP2C9 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.